Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications.
In: Family Practice News, 2023-11-01, S. 1-3
Online
Zeitungsartikel
Zugriff:
A systematic literature review and meta-analysis found that short-term use of JAK inhibitors for dermatologic indications does not appear to be associated with an increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolic events (VTE). The review included 35 randomized clinical trials with a total of 20,651 patients, and no significant differences were found between JAK inhibitors and placebo/active comparator in terms of MACE, all-cause mortality, or VTE. The study's findings provide reassurance to dermatologists who may have concerns about the safety of JAK inhibitors. However, the researchers noted limitations in the review, such as the lack of access to patient-level data and the short-term follow-up in most trials. Continued long-term data generation is needed to fully understand the risk of these events. [Extracted from the article]
Copyright of Family Practice News is the property of Frontline Medical Communications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications.
|
---|---|
Autor/in / Beteiligte Person: | Brunk, Doug |
Link: | |
Zeitschrift: | Family Practice News, 2023-11-01, S. 1-3 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
ISSN: | 0300-7073 (print) |
Schlagwort: |
|
Sonstiges: |
|